PSMA-targeted radiopharmaceuticals: An evolving approach to prostate cancer management

touchCONGRESS for touchONCOLOGY Listen to renowned prostate cancer expert Prof. Oliver Sartor review key data presented at the recent EMSO 2023 congress on new and emerging data that addresses key clinical questions on the use of radiopharmaceuticals in advanced prostate cancer. He also discusses with two additional leading experts, Prof. Francesco Ceci and Dr Heather Jacene, how these data may apply in clinical practice. Overview  Data reviews with Prof. Oliver Sartor Expert panel discussions with Prof. Francesco Ceci and Dr Heather Jacene on the themes below Clinical themes Refining the use of PSMA-targeted radiopharmaceuticals through optimal patient selections Expanding the use of PSMA-targeting radiopharmaceuticals in prostate cancer Novel agents and combination approaches to the use of PSMA-targeted radiopharmaceuticals in prostate cancer The internationally renowned expert faculty Prof. Oliver Sartor, Mayo Clinic, Rochester, MN, USA Prof. Francesco Ceci, European Institute of Oncology, IRCCS, Milan, Italy Dr Heather Jacene, Dana-Farber Cancer Institute, Boston, MA, USA This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Advanced Accelerator Applications, and is jointly provided by USF Health and touchIME. For further information visit our website: touchoncologyime.org/psma-targeted-radiopharmaceuticals-an-evolving-approach-to-prostate-cancer-management/